Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 12/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13327274 | 0.82 | POLB (0.52) | LMNAKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22397770 | 0.82 | POLB (0.52) | LMNAKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9310615 | 0.80 | NPSR1 (0.57) | PANK3LMNAHTTKMT2AMEN1 | |
| SCHEMBL5646412 | 0.79 | MEN1 (0.52) | PANK3LMNAHTTKMT2AMEN1 | |
| SCHEMBL13533786 | 0.79 | HRH3 (0.50) | KMT2ASMN1; SMN2ALDH1A1CYP1A2FABP7 | |
| SCHEMBL12295621 | 0.78 | HDAC1 (0.49) | LMNAHTTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3219970 | 0.77 | FABP5 (0.49) | LMNAKMT2ASMN1; SMN2ALDH1A1FABP7 | |
| SCHEMBL30824716 | 0.76 | TSHR (0.50) | LMNAKMT2ASMN1; SMN2ALDH1A1FABP7 | |
| SCHEMBL8222797 | 0.76 | TSHR (0.50) | LMNAKMT2ASMN1; SMN2ALDH1A1FABP7 | |
| SCHEMBL30555288 | 0.76 | TSHR (0.50) | LMNAKMT2ASMN1; SMN2ALDH1A1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071590-B2 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2011-12-06 | — | — | US | disclosed |
| EP-2145891-A1 | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL S.A. (FR) | 2010-01-20 | — | — | EP | disclosed |
| WO-2010004394-A1 | 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | WO | disclosed |
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009980-A1 | NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | Q6ZSR9, NQO2, RECQL | PANK3 2542/4885LMNA 3494/4885HTT 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.